Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus the chance to net up to $400 million in biobucks. Last…
Gilead Sciences has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area…
Gilead Sciences and Arcus Biosciences’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to 27 months, keeping alive one of the last remaining hopes for this…